{"id":55632,"date":"2023-04-10T13:04:13","date_gmt":"2023-04-10T11:04:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/"},"modified":"2023-04-10T13:04:13","modified_gmt":"2023-04-10T11:04:13","slug":"aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/","title":{"rendered":"Aviceda Therapeutics Announces Strategic Partnership with Queen\u2019s University Belfast (QUB)"},"content":{"rendered":"
\n

\nAviceda is partnering with world-renowned scientist Professor Christopher Scott and his teams at the Patrick G. Johnson Centre for Cancer Research at Queen\u2019s University Belfast to spearhead development of the next generation of glyco-immune therapeutics.<\/b><\/p>\n

\nAviceda Executives will participate in a Cancer Showcase Event as part of the 25th Anniversary of the Good Friday Agreement Conference at Queen\u2019s to highlight Northern Ireland\u2019s emerging global reputation in the translational oncology ecosystem.<\/b><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics<\/a>, a clinical-stage biotech company focused on developing next-generation immuno-modulators to treat diseases such as cancer, today announced a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen\u2019s University Belfast (Queen\u2019s). Aviceda\u2019s HALOS\u2122 (H<\/i><\/b>igh-A<\/b>ffinity L<\/b>igands o<\/b>f S<\/b>igelcs<\/i>) nanotechnology platform, based on an invention from the research team led by Professor Chris Scott, Scientific Co-Founder and Chief Scientific Officer of Aviceda & Interim Dean of Research, Faculty of Medicine, Health, and Life Sciences, at Queen\u2019s<\/b>, <\/b>harnesses the power of glycobiology to modulate the innate immune system to develop next-generation breakthrough therapeutics, with a focus on immuno-oncology.<\/p>\n

<\/a><\/p>\n

\nThis revolutionary technology was made possible only through collaborative research on the island of Ireland. The founding of Aviceda Glycotech Ltd, an oncology-focused spin-off company from Aviceda Therapeutics and Queen\u2019s, based in Northern Ireland, highlights US-Ireland translational research collaborations which are a direct legacy of the Good Friday Agreement. This historic agreement brought an end to 30 years of conflict and allowed Belfast to develop the Patrick G Johnston Centre for Cancer Research as an international powerhouse in precision oncology. Aviceda Glycotech looks forward to this collaboration aimed at developing the next generation of cancer checkpoint immune therapeutics in Belfast.<\/p>\n

\n\u201cIt is critical that the biotechnology industry and academic institutions work together to foster innovation and accelerate drug development for diseases with significant unmet medical needs, and Queen\u2019s is an ideal partner with a substantial track record in innovation to support us in this effort,\u201d said Doctor Mohamed Genead, M.D., Co-Founder & President, and Chief Executive Officer<\/b>. \u201cWe are excited to work with the Queen\u2019s team in realizing our vision of developing next generation glyco-therapeutics together.\u201d<\/p>\n

\nAs part of the 25th<\/sup> Anniversary of the Belfast Good Friday Agreement (Agreement 25), Dr. Genead<\/i><\/b>, will participate on an expert panel and Professor Scott<\/i><\/b> will chair a session during the Cancer Knows No Borders<\/i> Agreement 25 Showcase Event at Queen\u2019s to recognize the impact of the Good Friday Agreement on cancer research and cancer care. Professor Mark Lawler, Professor of Digital Health, Chair in Translational Cancer Genomics at Queen\u2019s, Co-Lead of the All Island Cancer Research Institute and organizer of the Cancer Showcase event said, \u201cThis Showcase Event during the Agreement 25 Conference will reflect on the legacy and impact of the Good Friday Agreement on cancer research at Queen\u2019s and how it is driving the development of an innovation cluster in Northern Ireland that can attract biotech companies like Aviceda Glycotech to benefit from the talent, infrastructure and precision medicine focus that Northern Ireland has to offer.\u201d<\/p>\n

\n\u201cWe are excited and honored to be in Belfast on this historic occasion and look forward to our collaboration with Queen\u2019s as we aim to develop new approaches that will hopefully lead one day to the conquering of hard-to-treat cancers, building on a technology that was originally pioneered in Northern Ireland,\u201d said Michael Tolentino MD, Co-Founder & Chief Technology Officer of Aviceda<\/b>.<\/p>\n

\n\u201cThis commercial investment is testament to collaboration across the island of Ireland and the US. It shows the potential of Northern Ireland to become an internationally renowned life and health science hub, aligning with Belfast Region City Deal investments in data science and clinical trial provision and the All-Island Cancer Research Institute. These developments are essential cogs in an ecosystem that will drive the discoveries we make in our laboratories into treatments that can alleviate suffering of patients worldwide,\u201d said Professor Scott.<\/b><\/p>\n

\nAbout Queen\u2019s University & the Patrick G Johnston Centre for Cancer Research<\/b><\/p>\n

\nThe Patrick G Johnston Centre for Cancer Research<\/a> at Queen\u2019s University Belfast is a prestigious, world-class medical center that significantly impacts all of society \u2013 regionally, nationally, and globally \u2013 through innovative cancer research and education. Its mission is to improve patient outcomes, train the next generation of scientists and clinicians, and enhance the competitiveness of the UK life sciences sector.<\/p>\n

\nResearchers at the Patrick G Johnston Centre for Cancer Research (PGJCCR) are finding new ways to advance cancer treatment. They are taking the lead in personalized \u201cprecision\u201d medicine and are working with partners around the world to pioneer advances in patient care.<\/p>\n

\nThe PGJCCR undertakes basic, translational, and clinical research into a range of cancer types including Solids tumors, blood cancers, tumor epidemiology and early detection, bioinformatics, therapy resistance, and advanced radiotherapy.<\/p>\n

\nAbout Aviceda Therapeutics<\/b><\/p>\n

\nAviceda is a clinical stage private biotechnology company located in Cambridge, Massachusetts, USA with a proprietary nano-technology HALOS\u2122 platform and an IND-ready ophthalmic lead product for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). AVD-104 is an intravitreal nanoparticle molecule with a unique dual mechanism of action for the treatment of GA through its modulation of critical inflammatory pathways: 1) Direct inhibition of the activity of damaging phagocytic macrophages and repolarization of activated macrophages to their resolution state, and 2) Inhibition of complement cascade amplification. AVD-104 has demonstrated robust in-vitro\/vivo efficacy with inhibition of both inflammatory & complement pathways and the potential for every 4-6-month dosing. Outstanding safety has been demonstrated in multiple animal models, including non-human primates, in which there were no signs of intra-ocular inflammation. In addition, AVD-104 has demonstrated equivalent prevention of neovascularization compared to aflibercept (Eylea) in a well-established ocular CNV model.<\/p>\n

\nAlong with AVD-104, Aviceda has a broad pipeline of products in development in ophthalmology and other therapeutic areas such as neurology, oncology, fibrosis, and immunology.<\/p>\n

\nLearn more about Aviceda Therapeutics.<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nFor Investors Relations & Media:
\n
info@avicedarx.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Aviceda is partnering with world-renowned scientist Professor Christopher Scott and his teams at the Patrick G. Johnson Centre for Cancer Research at Queen\u2019s University Belfast to spearhead development of the next generation of glyco-immune therapeutics. Aviceda Executives will participate in a Cancer Showcase Event as part of the 25th Anniversary of the Good Friday Agreement … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55632","6":"format-standard","7":"category-industry"},"yoast_head":"\nAviceda Therapeutics Announces Strategic Partnership with Queen\u2019s University Belfast (QUB) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aviceda Therapeutics Announces Strategic Partnership with Queen\u2019s University Belfast (QUB) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Aviceda is partnering with world-renowned scientist Professor Christopher Scott and his teams at the Patrick G. Johnson Centre for Cancer Research at Queen\u2019s University Belfast to spearhead development of the next generation of glyco-immune therapeutics. Aviceda Executives will participate in a Cancer Showcase Event as part of the 25th Anniversary of the Good Friday Agreement ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-10T11:04:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230412005004\/en\/1757611\/21\/AVICEDA_THERAPEUTICS_LOGO_MASTER.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Aviceda Therapeutics Announces Strategic Partnership with Queen\u2019s University Belfast (QUB)\",\"datePublished\":\"2023-04-10T11:04:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\\\/\"},\"wordCount\":1001,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230412005004\\\/en\\\/1757611\\\/21\\\/AVICEDA_THERAPEUTICS_LOGO_MASTER.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\\\/\",\"name\":\"Aviceda Therapeutics Announces Strategic Partnership with Queen\u2019s University Belfast (QUB) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230412005004\\\/en\\\/1757611\\\/21\\\/AVICEDA_THERAPEUTICS_LOGO_MASTER.jpg\",\"datePublished\":\"2023-04-10T11:04:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230412005004\\\/en\\\/1757611\\\/21\\\/AVICEDA_THERAPEUTICS_LOGO_MASTER.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230412005004\\\/en\\\/1757611\\\/21\\\/AVICEDA_THERAPEUTICS_LOGO_MASTER.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aviceda Therapeutics Announces Strategic Partnership with Queen\u2019s University Belfast (QUB)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aviceda Therapeutics Announces Strategic Partnership with Queen\u2019s University Belfast (QUB) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/","og_locale":"en_US","og_type":"article","og_title":"Aviceda Therapeutics Announces Strategic Partnership with Queen\u2019s University Belfast (QUB) - Pharma Trend","og_description":"Aviceda is partnering with world-renowned scientist Professor Christopher Scott and his teams at the Patrick G. Johnson Centre for Cancer Research at Queen\u2019s University Belfast to spearhead development of the next generation of glyco-immune therapeutics. Aviceda Executives will participate in a Cancer Showcase Event as part of the 25th Anniversary of the Good Friday Agreement ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-10T11:04:13+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230412005004\/en\/1757611\/21\/AVICEDA_THERAPEUTICS_LOGO_MASTER.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Aviceda Therapeutics Announces Strategic Partnership with Queen\u2019s University Belfast (QUB)","datePublished":"2023-04-10T11:04:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/"},"wordCount":1001,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230412005004\/en\/1757611\/21\/AVICEDA_THERAPEUTICS_LOGO_MASTER.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/","url":"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/","name":"Aviceda Therapeutics Announces Strategic Partnership with Queen\u2019s University Belfast (QUB) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230412005004\/en\/1757611\/21\/AVICEDA_THERAPEUTICS_LOGO_MASTER.jpg","datePublished":"2023-04-10T11:04:13+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230412005004\/en\/1757611\/21\/AVICEDA_THERAPEUTICS_LOGO_MASTER.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230412005004\/en\/1757611\/21\/AVICEDA_THERAPEUTICS_LOGO_MASTER.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/aviceda-therapeutics-announces-strategic-partnership-with-queens-university-belfast-qub\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Aviceda Therapeutics Announces Strategic Partnership with Queen\u2019s University Belfast (QUB)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55632"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55632\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}